Satraplatin for Patients With Metastatic Breast Cancer (MBC)

You may be eligible if

• 1. Has cytologically or pathologically confirmed breast cancer that is metastatic
• 2. Must have had prior HerceptinÒ therapy if patient has HER2+ (overexpressing) breast cancer. HER2 is considered overexpressed if it is 3+ by IHC or if the gene is amplified by Flourescence in situ hybridization (FISH)
• 3. Has had no more than 1 prior chemotherapy regimen for MBC
• 4. Has had no prior platinum-based therapy
• 5. Has an ECOG Performance Status (PS) 0-2